Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

计划入组 4,000 人 · 首次发布于 2026 年 1 月 14 日

Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis

计划入组 70 人 · 首次发布于 2026 年 8 月 14 日

Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.

计划入组 5 人 · 首次发布于 2022 年 9 月 29 日

Transthyretin Amyloidosis Therapy (HuidaGene)

TTR gene therapy (transthyretin amyloidosis)

hATTR-PNS

ATSR LIMITED

Ireland

Alnylam's Nucresiran Shows Sustained TTR Reduction in Phase 1 ATTR Amyloidosis Trial

Alnylam Presents New Data at ESC Congress 2026 Reinforcing RNAi-Powered TTR Silencing in ATTR-CM and Hypertension

FDA Accepts Alnylam's Vutrisiran Application for ATTR Amyloidosis with Cardiomyopathy